CO7160032A2 - Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida - Google Patents

Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Info

Publication number
CO7160032A2
CO7160032A2 CO15003999A CO15003999A CO7160032A2 CO 7160032 A2 CO7160032 A2 CO 7160032A2 CO 15003999 A CO15003999 A CO 15003999A CO 15003999 A CO15003999 A CO 15003999A CO 7160032 A2 CO7160032 A2 CO 7160032A2
Authority
CO
Colombia
Prior art keywords
pyridin
ylmethylamino
quinazolin
sulfonamide
phenyl
Prior art date
Application number
CO15003999A
Other languages
English (en)
Inventor
Jayakumar S Warrier
Navnath Dnyanoba Yadav
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO7160032A2 publication Critical patent/CO7160032A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un compuesto de la Fórmula estructural Ien donde R es H o -PO3H, o una sal farmacéuticamenteaceptable del mismo. Los compuestos son útiles comoinhibidores de la función del canal de potasio y para eltratamiento y la prevención de arritmia, trastornos asociadosa IKur y otros trastornos mediados por la función del canaliónico.
CO15003999A 2012-06-11 2015-01-08 Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida CO7160032A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11

Publications (1)

Publication Number Publication Date
CO7160032A2 true CO7160032A2 (es) 2015-01-15

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15003999A CO7160032A2 (es) 2012-06-11 2015-01-08 Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida

Country Status (34)

Country Link
US (1) US9238666B2 (es)
EP (1) EP2858987B1 (es)
JP (1) JP6234450B2 (es)
KR (1) KR102092984B1 (es)
CN (1) CN104350048B (es)
AR (1) AR091402A1 (es)
AU (1) AU2013274619B2 (es)
BR (1) BR112014030629B1 (es)
CA (1) CA2876359C (es)
CL (1) CL2014003361A1 (es)
CO (1) CO7160032A2 (es)
CY (1) CY1120432T1 (es)
DK (1) DK2858987T3 (es)
EA (1) EA024692B1 (es)
ES (1) ES2675314T3 (es)
HK (1) HK1203928A1 (es)
HR (1) HRP20180815T8 (es)
HU (1) HUE039210T2 (es)
IL (1) IL236074A (es)
LT (1) LT2858987T (es)
MX (1) MX356699B (es)
MY (1) MY169219A (es)
NZ (1) NZ703632A (es)
PE (1) PE20150228A1 (es)
PH (1) PH12014502747A1 (es)
PL (1) PL2858987T3 (es)
PT (1) PT2858987T (es)
RS (1) RS57376B1 (es)
SG (1) SG11201408076WA (es)
SI (1) SI2858987T1 (es)
TN (1) TN2014000499A1 (es)
TW (1) TWI571470B (es)
WO (1) WO2013188254A1 (es)
ZA (1) ZA201500161B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのピロロピリダジン
CN105026399B (zh) * 2013-03-11 2017-06-23 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并三嗪类化合物
ES2969792T3 (es) * 2015-11-19 2024-05-22 Biohaven Therapeutics Ltd Profármacos de amina de compuestos farmacéuticos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
SK18822000A3 (sk) 1998-07-06 2001-12-03 Bristol-Myers Squibb Company Bifenylsulfónamidy ako duálne antagonisty angiotenzínového a endotelínového receptora
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
NZ598516A (en) * 2009-09-03 2013-02-22 Bristol Myers Squibb Co Quinazolines as potassium ion channel inhibitors
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
AU2011270701B2 (en) * 2010-06-24 2015-05-14 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
EP2970199A1 (en) * 2013-03-11 2016-01-20 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
HUE039210T2 (hu) 2018-12-28
ZA201500161B (en) 2017-04-26
BR112014030629B1 (pt) 2021-12-21
CN104350048A (zh) 2015-02-11
IL236074A (en) 2016-08-31
MY169219A (en) 2019-03-19
TN2014000499A1 (en) 2016-03-30
SI2858987T1 (en) 2018-06-29
CA2876359C (en) 2020-01-21
PL2858987T3 (pl) 2018-08-31
PE20150228A1 (es) 2015-02-19
US9238666B2 (en) 2016-01-19
KR102092984B1 (ko) 2020-03-24
AU2013274619B2 (en) 2017-09-28
CL2014003361A1 (es) 2015-05-29
RS57376B1 (sr) 2018-08-31
NZ703632A (en) 2016-01-29
PH12014502747B1 (en) 2015-02-02
EA024692B1 (ru) 2016-10-31
EP2858987A1 (en) 2015-04-15
JP2015521598A (ja) 2015-07-30
MX356699B (es) 2018-06-11
HK1203928A1 (en) 2015-11-06
KR20150023667A (ko) 2015-03-05
WO2013188254A1 (en) 2013-12-19
BR112014030629A2 (pt) 2017-06-27
CN104350048B (zh) 2016-12-07
TWI571470B (zh) 2017-02-21
MX2014014525A (es) 2015-02-24
JP6234450B2 (ja) 2017-11-22
TW201402592A (zh) 2014-01-16
US20150175641A1 (en) 2015-06-25
HRP20180815T8 (hr) 2019-02-08
HRP20180815T1 (hr) 2018-06-29
PH12014502747A1 (en) 2015-02-02
IL236074A0 (en) 2015-02-01
DK2858987T3 (en) 2018-07-30
AU2013274619A1 (en) 2015-01-29
AR091402A1 (es) 2015-02-04
EA201492256A1 (ru) 2016-05-31
LT2858987T (lt) 2018-07-10
SG11201408076WA (en) 2015-01-29
CY1120432T1 (el) 2019-07-10
CA2876359A1 (en) 2013-12-19
PT2858987T (pt) 2018-07-04
ES2675314T3 (es) 2018-07-10
EP2858987B1 (en) 2018-04-25

Similar Documents

Publication Publication Date Title
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
PH12015502036A1 (en) Inhibitors of the kynurenine pathway
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CR20140231A (es) Derivados de ácido benzotiazol-6-il acético y su uso para tratar una infección por vih
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
NI201500112A (es) Compuestos de azabencimidazol como inhibidores de isozimas pde4 para el tratamiento del snc y otros trastornos.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
EA201690473A1 (ru) Комбинированный состав двух противовирусных соединений
CR20140026A (es) Compuestos para el tratamiento y profilaxis de la enfermedad del virus sincicial respiratorio
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
UY35381A (es) Pirrolotriazinas como inhibidores del canal del ion potasio
CU20130126A7 (es) Inhibidores sustituidos de acetil-coa carboxilasa
CL2018002583A1 (es) Derivado de morfolina
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
CO7160032A2 (es) Profarmacos de ácido fosforamidico de 5-[5-fenil-4-(piridin-2-ilmetilamino)quinazolin-2-il]piridin-3-sulfonamida
DOP2013000251A (es) Isoxazolinas como agentes terapeuticos
PE20141021A1 (es) DERIVADOS DE TIENO [2,3-d] PIRIMIDINA COMO INHIBIDORES DEL CANAL DE POTASIO
NZ707087A (en) Novel flavonoid compounds and uses thereof